Autopsy report · NCT04984811

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

“sponsor decision (not for safety)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 33 participants enrolled.
• Results were posted on the registry 1 year 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

NeoImmuneTech

Sponsor type

Industry

Conditions

Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Non Small Cell Lung Cancer

Interventions

efineptakin alfa; Atezolizumab

Participants

33

Sites

22

Countries

United States

Trials that died the same way

• Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
  “Sponsor decision (not due to safety concerns)” (98% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (97% match in meaning)
• An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
  “Sponsor decision; not a safety decision” (97% match in meaning)
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
  “Sponsor decision, not related to safety concerns” (92% match in meaning)
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
  “Sponsor decision, not for safety reasons.” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.